Published in Clin Cancer Res on December 12, 2011
Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res (2014) 1.66
Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer. Nat Commun (2016) 1.65
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol (2014) 1.43
Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res (2013) 1.43
Small cell carcinoma of the prostate. Nat Rev Urol (2014) 1.31
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Targeting cell cycle and hormone receptor pathways in cancer. Oncogene (2013) 1.10
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal (2014) 1.03
Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol (2014) 0.98
High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer (2013) 0.91
Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer. Int J Mol Sci (2013) 0.89
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res (2015) 0.86
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res (2015) 0.85
Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol (2015) 0.83
Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation. Mol Cell Pharmacol (2015) 0.81
Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res (2015) 0.80
Characterization of the genomic architecture and mutational spectrum of a small cell prostate carcinoma. Genes (Basel) (2014) 0.80
Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics (2016) 0.78
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. Oncogene (2016) 0.78
Molecular aspects of prostate cancer with neuroendocrine differentiation. Chin J Cancer Res (2016) 0.78
Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers. Oncotarget (2016) 0.75
Castrate-resistant prostate cancer: postdocetaxel management. Curr Opin Urol (2013) 0.75
The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle (2017) 0.75
Patient-derived xenografts as in vivo models for research in urological malignancies. Nat Rev Urol (2017) 0.75
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics (2003) 5.40
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol (2009) 2.50
Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A (2008) 2.47
DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate (2007) 2.37
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol (1998) 2.10
CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene (1993) 1.95
Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene (2004) 1.82
Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci (2008) 1.81
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Neuroendocrine differentiation in prostatic carcinoma. Prostate (1999) 1.74
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res (1998) 1.65
Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol (2010) 1.60
Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene (2010) 1.43
Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol (2006) 1.42
The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung. Hum Pathol (2003) 1.40
Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer (2007) 1.39
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 1.33
Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J (2011) 1.33
Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res (2000) 1.30
Mitosis as an anti-cancer target. Oncogene (2011) 1.29
Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol (1991) 1.29
Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate (2010) 1.24
Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol (2009) 1.21
TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol (2010) 1.17
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol (1998) 1.17
RB's original CIN? Genes Dev (2010) 1.14
Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol (2001) 1.13
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol (2007) 1.13
Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch (1999) 1.05
Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features. Am J Pathol (2010) 1.02
Retinoblastoma regulatory pathway in lung cancer. Curr Mol Med (2006) 0.95
Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. J Pathol (2004) 0.94
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem (2011) 0.92
Spindle assembly checkpoint protein Cdc20 transcriptionally activates expression of ubiquitin carrier protein UbcH10. J Biol Chem (2011) 0.91
Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors. Mod Pathol (2004) 0.88
The histogenesis of small cell carcinoma of the prostate. An immunohistochemical study. Cancer (1984) 0.87
Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch Pathol Lab Med (2000) 0.84
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology (2007) 4.17
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
Identification of transcribed sequences in Arabidopsis thaliana by using high-resolution genome tiling arrays. Proc Natl Acad Sci U S A (2005) 3.21
High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol (2008) 3.09
CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A (2008) 3.04
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology (2005) 2.71
Predicting protein functions from redundancies in large-scale protein interaction networks. Proc Natl Acad Sci U S A (2003) 2.63
Season of conception in rural gambia affects DNA methylation at putative human metastable epialleles. PLoS Genet (2010) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol (2008) 2.00
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95
Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2005) 1.91
Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol (2009) 1.90
Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer (2004) 1.90
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
TDRD3 is an effector molecule for arginine-methylated histone marks. Mol Cell (2010) 1.80
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer (2006) 1.75
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A (2009) 1.74
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy. Urology (2002) 1.74
Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74
Molecular mechanism by which the nucleoid occlusion factor, SlmA, keeps cytokinesis in check. EMBO J (2010) 1.72
Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J Bone Miner Res (2009) 1.71
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res (2012) 1.68
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol (2012) 1.65
The B subunit of the CCAAT box binding transcription factor complex (CBF/NF-Y) is essential for early mouse development and cell proliferation. Cancer Res (2003) 1.63
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis (2008) 1.57
Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56
Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol (2009) 1.53
Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53
Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53
Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53
Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res (2010) 1.53
African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men. Cancer (2006) 1.52
Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol (2013) 1.52
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49